NCT00335075View on ClinicalTrials.gov

Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)

PHASE3CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

March 2, 2005

Primary Completion Date

February 23, 2006

Study Completion Date

February 23, 2006

Conditions
GlioblastomaAstrocytoma
Interventions
DRUG

Temozolomide

Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.

DRUG

Semustine

Semustine orally once every 28 days at a dose of 150 mg/m2/day.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00335075 - Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) | Biotech Hunter | Biotech Hunter